Coya Therapeutics, Inc. (COYA) is a clinical-stage biotechnology company on the Nasdaq that is developing therapies designed to enhance regulatory T cells (Tregs), the immune cells that help keep inflammation in check. Its lead program, COYA 302, is being studied in amyotrophic lateral sclerosis (ALS), with the shares recently trading near $3.21. The question for investors is whether the stock can climb toward the roughly $15 level that current analyst price targets imply.
The $15 central target reflects six current analyst price targets, each attributed to a named firm and reviewed against multiple data providers. They include Roth MKM ($12), Chardan Capital ($14), D. Boral Capital ($15), BTIG ($16), Lake Street ($17), and H.C. Wainwright ($18). The arithmetic mean of these six figures is approximately $15.33, which rounds to a $15 stock price target. The low-to-high range is $12 to $18, and all six firms maintain Buy ratings, with no Holds or Sells in the current group.
The wide range reflects genuine disagreement about how much value to assign to COYA 302 ahead of its pivotal readout. Higher targets emphasize the size of the ALS market opportunity, the FDA's Fast Track designation granted in 2026, and the potential for a substantial re-rating if the trial succeeds. Lower targets apply a deeper discount for execution risk and the long runway before any potential commercialization. None of these figures should be read as a guarantee; they represent research-horizon estimates, not forecasts of near-term trading.
Shares have fallen sharply over the past year, recently changing hands near $3.21, close to the lower end of a 52-week range that has extended from roughly $2.72 to above $6.60. Moving from $3.21 to $15 implies upside of about 367%, which is a very large required move for a stock whose near-term value is tied to a single pivotal clinical program.
The most likely path toward the target runs through the ALSTARS trial of COYA 302 in ALS. Enrollment is complete at 137 participants, and the company expects topline data from the 24-week double-blind treatment phase in early Q2 2027. Because the company generates only modest collaboration revenue and has no approved product, the share price is heavily dependent on clinical catalysts and financing rather than earnings or cash flow, which remain negative.
From a technical standpoint, the shares have been in a pronounced downtrend, with the recent $2.72 area acting as an important support zone near the 52-week low. The current price near $3.21 sits above that level but well below prior highs above $6.60. A sustained recovery would first need to reclaim intermediate resistance around the $4 to $5 zone before the much higher analyst targets become relevant. These levels illustrate the scale of the gap between the current price and the $15 central target.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may use different assumptions. For Coya, the pivotal event is the ALSTARS topline readout now expected in early Q2 2027. Investors should also monitor any FTD biomarker data expected in the first quarter of 2027, updates on the open-label extension beginning in November 2026, cash position and any financing announcements, and any changes in analyst ratings or targets as the readout approaches. No definitive forecast is offered here.
For traders seeking a more systematic view of COYA and thousands of other securities, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These tools are designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Consider exploring the signals as part of a broader research process.
Whether Coya Therapeutics (COYA) can reach $15 hinges overwhelmingly on the outcome of the ALSTARS trial. The $15 central target — the mean of six current analyst targets ranging from $12 to $18 — sits roughly 367% above the recent price, a very large move that is only plausible, in the view of these analysts, if COYA 302 demonstrates meaningful efficacy in ALS. The completed enrollment, Fast Track designation, and cash runway past the readout are meaningful supports, while clinical failure, dilution, and execution delays are the principal obstacles. The next major signpost is the early Q2 2027 topline readout, and investors should watch that catalyst alongside cash, financing, and any analyst revisions closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, COYA has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if COYA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To COYA | 1D Price Change % | ||
|---|---|---|---|---|
| COYA | 100% | +1.58% | ||
| EDIT - COYA | 51% Loosely correlated | -4.99% | ||
| VIR - COYA | 48% Loosely correlated | -0.15% | ||
| INMB - COYA | 44% Loosely correlated | N/A | ||
| CADL - COYA | 44% Loosely correlated | -1.39% | ||
| RXRX - COYA | 44% Loosely correlated | +1.13% | ||
More | ||||